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ACE inhibition reduces proteinuria, glomerular lesions and extracel-
lular matrix production in a normotensive rat model of immune complex
nephritis. We studied the effect of the angiotensin converting enzyme
(ACE) inhibitor, quinapril, on the clinical and morphological lesions of a
normotensive model of immune complex nephritis. Untreated rats devel-
oped massive nephrotic syndrome, intense cell proliferation and glomer-
ular and tubulointerstitial lesions. In the renal cortex of nephritic rats
there was a significant increase in gene expression of TGF-1, fibronectin
and collagens, and ACE activity. Systolic blood pressure remained normal
with progression of the disease. Administration of quinapril for three
weeks to animals with glomerular lesions (proteinuria 20 to 50 mg/day)
avoided the development of intense proteinuria (79 28 vs. 589 73
mg/day, P < 0.001) and decreased cell proliferation, glomerulosclerosis,
tubulointerstitial lesions, and inflammatory infiltrates. Cortical gene ex-
pression of TGF-pl and matrix proteins was also diminished. ACE activity
was inhibited by 68% in renal cortex. These results show that quinapril
administration to normotensive rats with immune complex nephritis
decreases proteinuria and glomerular and tubulointerstitial lesions, prob-
ably modulating the local angiotensin II generation and its effects on cell
growth, TGFI3 and matrix protein synthesis.
The proliferation of glomerular cells and the additional pro-
duction of matrix proteins have been associated with the onset of
proteinuria, glomeruloscierosis and progressive renal failure in a
large number of animal models [1, 21. Although the precise
mechanisms leading to matrix expansion are not known, there is
evidence that growth factors and cytokines released by infiltrating
leukocytes, platelets and resident glomerular cells play a signifi-
cant role [1, 2].
Studies in the last few years have suggested that the renin-
angiotensin system (RAS) may play a role in the pathogenesis of
tissue damage [3, 4]. Early indications came from studies in which
the treatment with ACE inhibitors reduced proteinuria and
sclerosis in experimental models of nephritis, characterized by
elevated systemic and glomerular capillary pressure, as the rem-
nant kidney model and diabetic nephropathy [5—7]. Several inves-
tigators have attributed this beneficial effect to hemodynamic
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causes [5—9], while others have suggested that ACE inhibitors
could have a primary effect on the permeability of the glomerular
basement membrane [10—13]. Likewise, in chronic nephrosis
induced by puromycin aminonucleoside, the administration of
enalapril attenuated proteinuria, glomerular sclerosis and tubulo-
interstitial damage [14, 15].
The interest in the participation of RAS in tissue damage has
recently increased. Angiotensin II (Ang II) promotes cell prolif-
eration and synthesis of extracellular matrix proteins in different
cells [16—18]. Furthermore, in renal cells, such as mesangial cells
[19], tubular epithelial cells [20] and interstitial fibroblasts [211,
Ang II induces expression and synthesis of growth factors which
participate in tissue remodeling and sclerosis.
Although most human glomerular diseases are of immune
origin, little information is available about the effect of ACE
inhibitors on the evolution of immune complex-mediated glomer-
ular injury. Nevertheless, recent reports have shown that ACE
inhibitors may decrease proteinuria even in normotensive patients
[22], suggesting the importance of local RAS in kidney injury.
For those reasons, the current study was designed to determine
the effect of quinapril, an ACE inhibitor with intense tissular
binding [23, 24], on a normotensive model of immune nephritis
induced in rats by repeated injections of ovalbumin [25]. This
model is characterized by heavy proteinuria, the presence of
immune complexes in all glomerular areas, intense cellular pro-
liferation and mesangial matrix expansion [25, 26]. We investi-
gated whether the therapeutic effect of ACE inhibition involves
attenuation of renal expression of transforming growth factor-fl
(TGF-/31) and extracellular matrix proteins in rats with nephritis.
Finally, in order to assess the importance of renal ACE inhibition
by quinapril, we determined the ACE activity in the kidney tissue.
Our results show that the administration of quinapril to rats
with active nephritis decreased proteinuria, morphological le-
sions, and gene expression of TGF-f31 and extracellular matrix
proteins. These data support the hypothesis that the local RAS
could play an important role in the pathogenesis of the glomerular
and interstitial damage in this model. This study provides com-
pelling evidence for the use of ACE inhibitors in immune complex
nephritis with overt glomerular injury, even in the absence of
systemic hypertension.
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Fig. 2. Urinaty protein excretion rate during three weeks of observation.
Proteinuria in untreated (—) or quinapril-treated rats (). Untreated rats
developed massive proteinuria reaching the value of 589 73 mg/day.
Quinapril treatment prevented the development of intense proteinuria (79
28 mg/day at 3 weeks, < 0.001 vs. untreated rats). Proteinuria
remained in the normal range (<5 mg/day) in healthy rats, treated or not
with quinapril (not shown). Data are shown as mean SEM. N = 10 to 12
per group.
Methods
Experimental design
Studies were conducted in normotensive female Wistar rats
with initial weights of 200 to 220 g (obtained from the Fundación
Jimenez DIaz animal facilities). Immune complex nephritis was
induced according to a previously described protocol [25, 26,
shown in Figure 1. Briefly, rats received an initial subcutaneous
injection of 5 mg of ovalbumin (OVA, Sigma Chemicals, St. Louis,
MO, USA) in complete Freund's adjuvant (CFA) (Difco, Detroit,
MI, USA), and three weeks afterwards, the same dose was given
in incomplete Freund's adjuvant (IFA; Difco). One week later,
daily intraperitoneal administration of 10 mg ovalbumin was
started. Proteinuria appeared around the 9th week. When pro-
teinuria reached 20 to 50 mg/day, animals were randomly distrib-
uted into two groups:
Untreated group. Animals with spontaneous development of
nephritis.Quinapril-treated. Animals treated with the ACE inhibitor
quinapril (as powdered hydrochloride, a gift from Parke Davis,
Fig. 1. Schedule of experimental protocol for the
induction of immune complex nephritis. Immune
complex nephritis was induced in normotensive
rats. When proteinuria reached 20 to 50 mg/day
1 0 11 1 2 animals were randomly distributed into two
groups: quinapril-treated (33 10 mg/day, N =
12) and untreated (30 14 mg/day, N = 12;P = NS). After three weeks of study animals
were sacrificed.
Table 1. Biochemical parameters
Group (N)
.Total protein
g/dl
Cholesterol Creatinine
mg/dl
Untreated 4.6 0.5' 330 11C 1.00 0.1C
nephritis (6)
Quinapril-treated 5.9 0.la 161 20 0.9 001h
nephritis (11)
Healthy controls 6.5 0.3 65 13 0.8 0.1
(12)
Quinapril 6.5 0.3 65 22 0.8 0.07
controls (12)
No drug Quinapril
Fig. 3. Blood pressure measurement in all groups of animals. Systolic blood
pressure remained stable in all groups. Bars represent mean SEM at the
end of the period of study. N 5 to 6 per group.
Barcelona, Spain) at a concentration of 100 mg/liter, added to the
drinking water and replaced every 48 hours.
Three weeks after the onset of proteinuria, animals were
sacrificed, blood collected and kidneys removed. A parallel con-
trol group of animals of the same age, with or without treatment,
was also studied.
Biochemistty
Urine was collected periodically from rats housed for 24 hours
in metabolic cages with access to water only. Proteinuria was
measured by the sulfosalicylic acid method.
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Fig. 4. Effect of quinapril treatment on
glomerular and tubulointerstitial damage. (A)
Microphotograph shows glomerulus from a
nephritic rat that has been stained with Masson
trichrome. Note the expansion of the mesangial
area, cellular proliferation and sclerotic lesions.
(B) In contrast, the glomerulus from a
quinapril-treated rat shows a slight increment in
the mesangium. Magnification X600.
At the end of the study period, serum levels of creatinine, total
protein and cholesterol were determined according to standard
methods. Creatinine clearance was calculated from three urine
samples taken 72 hours before the animal was sacrificed.
Blood pressure measurement
Systolic arterial blood pressure was measured in conscious,
restrained rats by a tail-cuff sphygnomanometer (NARCO Bio-
systems, CO, USA). The blood pressure value for each rat was
calculated as the average of three separate measurements at each
session.
Kidney tissue processing
At the time of sacrifice, the animals were fasted overnight and
anesthesized with 5 mg/100 g sodium pentobarbital. The kidneys
were perfused in vivo via the abdominal aorta with 100 ml of
normal saline at 4°C, while the left renal vein was punctured to
permit the perfusate to drain [27]. Blood samples were collected,
centrifugated (2000 g for 10 mm) and aliquots were stored at
—80°C for ACE activity determination. The kidneys were re-
moved immediately and further processed for histological studies,
ACE determination and RNA extraction.
Renal histopathological studies
All histological studies were performed without the observer
knowing to which group the animals belonged (double blind
study).
Tissue for light microscopy was fixed in buffered formalin and
embedded in paraffin. Sections (2 to 3 xm thickness) were
prepared and stained with hematoxylin-eosin, Masson trichrome
and periodic acid-Schiff. Glomeruloscierosis was defined as the
disappearance of cellular elements from the tuft, the collapse of
capillary lumens, and/or the folding of the glomerular basement
membrane with entrapment of amorphous material. Mesangial
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Fig. 4. (C) A representative microphotograph
of an untreated rat stained with hematoxylin-
eosin. Note the flattening of tubular cells,
tubular dilation and presence of protein casts.
In addition, an increase in mononuclear cell
infiltration was present in the interstitium.
(D) Almost normal tubulointerstitial
morphology was observed in quinapril-treated
rats. Magnification X 100.
expansion was defined by the presence of increased amounts of
material in the mesangial region that reacted positively with a
periodic acid-Schiff stain.
The glomerular immune deposits were semiquantitatively
scored, as previously described [28]: 0+, none; 1+, isolated
mesangial deposits; 2+, mesangial deposits and subendothelial
deposits in less than 50% of the glomeruli; 3+, mesangial deposits
and subendothelial deposits in more than 50% of the glomeruli.
Tissue for immunohistochemistiy and immunofluorescence was
embedded in OCT (Tissue-Tek, Miles, Elkhart, IN, USA) snap-
frozen in liquid nitrogen and stored at —80°C until the study.
The quantification of the infiltrating glomerular and interstitial
cells was performed by using an indirect immunoperoxidase
technique [291. Only the cells with a nucleus that could be clearly
identified were counted. The counting was done by magnifying the
images. In the interstitium, areas of 0.45 mm2 were counted. The
mean number of cells per glomerular cross section was deter-
mined by evaluating 50 glomeruli in each renal section. The
monoclonal antibodies employed were the following: Ox 1 (leuko-
cyte common antigen, LCA), W3113 (T lymphocytes, LT) (Se-
ralab, Sussex, UK) and ED1 (monocytes/macrophages) (Serotec,
Oxford, UK).
To examine the distribution and intensity of fibronectin and
collagens, indirect immunofluorescence was employed. Frozen
tissues were sectioned at 4 tm thickness using a cryostat. Air-
dried sections were fixed in cold acetone and incubated with
antibodies against extracellular matrix proteins. Primary antibod-
ies used were rabbit anti-rat fibronectin [30] and anti-rat collagen
type III (Chemicon, Temecula, CA, USA), and goat anti-rat
collagen type IV (UNLB, Birmingham, UK). The secondary
antibodies were FITC-labeled goat anti-rabbit IgG or FITC-
labeled donkey anti-goat IgG (Binding Site, Birmingham, UK).
As control experiments, tissue sections were incubated with
normal rabbit serum, followed by FITC-labeled antibodies or
secondary antibody alone. The slides were evaluated according to
a semiquantitative score, as previously described [29].
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Fig. 5. Semiquantitative analysis of giomerular and tubular damage in rats
with nephritis. Bars represent semiquantitative score of 6 untreated () or
quinapril-treated () rats. The values are expressed as mean SEM. *P <
0.05; ** < 0.005. There was no difference between healthy-controls and
quinapril-treated control rats (not shown).
To localize the immune deposits rabbit FITC-labeled anti-rat
IgG (Binding Site) was used for direct immunofluorescence.
Kidney mRNA isolation and hybridization studies
Tissue was divided in cortex and medulla, snap-frozen in liquid
nitrogen and stored at —80°C until study. Kidney tissue was
homogenized with a politron. RNA was obtained by the acid
guanidine-thiocyanate-phenol-chloroform method [31] and quan-
tified by absorbance at 260 nm in duplicate.
For quantitative studies, slot-dot hybridization was performed
with serial dilutions of total RNA after formaldehyde denatur-
ation. Four concentrations from each sample (serial dilution 1:2
from 40 jxg) were blotted to nylon filters using a slot-dot appara-
tus. RNA was fixed by baking at 80°C for 90 minutes [32].
For Northern blot analysis, equal amounts of RNA (40 jig)
were denatured and electrophoresed in a 1% agarose-formalde-
hyde gel and transferred to nylon membranes (Genescreen, New
England Nuclear, Boston, MA, USA). By means of ethidium
bromide staining we determined in each gel the equivalent
loading of RNA and its absence of degradation, the position of
the 28S and I 8S ribosomal RNA, and the efficacy of capillary
transfer. RNA was fixed to the nylon membrane by baking at 80°C
for 90 minutes.
The cDNA probes used were (c1)I (Hf677), (al)III (Hf939)
and (x1)IV (pCVIV-1-PE16) collagens (obtained from American
Type Culture Collection, Rockville, MD, USA). Probes were
prepared as described previously [31] and radiolabeled by nick
translation method (Boehringer Mannheim, Germany) with
a-32[P]dCTP (DuPont, Boston, MA, USA). The eDNA probes of
rat fibronectin (SR270), used as 270 bp EcoRI fragment (provided
by R.O. Hynes, Massachusetts Institute of Technology [33]) and
murine TGF-131, used as a 279 bp EcoRI fragment (a gift from
F.N. Ziyadeh, University of Pennsylvania [34]) were radiolabeled
by random primer method (Boehringer Mannheim) with
a-32[P]dCTP.
The membranes were prehybridized at least for four hours at
42°C in 50% formamide, 1% SDS, 5 >< SSC, 5 X Denhardt's
solution, 0.25 mg/mI denatured salmon sperm DNA and 50 ms
sodium phosphate buffer pH 6.5. Hybridization was carried out at
42°C overnight with 20% dextran sulfate and a-32[P]-denatured
probe. The filters were washed using a 2 x SSC, 0.1% SDS, for 30
minutes at room temperature and then twice with 0.2 X SSC,
0.1% SDS, at 55°C for 15 minutes. Blots were reutilized by
stripping. Autoradiography was performed by standard methods.
Autoradiography films were scanned using the Image Quant
densitometer (Molecular Dynamics, Sunnyvale, CA, USA). To
determine the efficiency of dot blot experiments, a lineal regres-
sion analysis was performed from the data obtained using only
those where the correlation was r = 0.99. For quantitative
comparisons, the density of the bands was corrected by the density
of 28S at the same dilution. The resulting values were then divided
by the values for control animals. Therefore the data presented
show the fold change of mRNA relative to control animals.
Measurement of ACE activity
Tissue for ACE activity determinations was dissected in cortex
and medulla, frozen in liquid nitrogen and stored at —80°C until
its study. Samples were homogenized in distilled water and
centrifuged at 12000 g for 10 minutes at 4°C. The resulting
supernatant was used for analysis of tissue ACE activity.
The glomeruli were isolated using the graded sieving technique
[35], washed twice in PBS, and resuspended in distilled water.
Samples were homogenized and spun down at 12000 g for five
minutes at 4°C. The resulting supernatant was used for analysis of
ACE activity. All glomerular preparations used consisted of more
than 95% glomeruli with minimal tubular contamination.
The brush border membranes were isolated from renal cortex,
using the method of Malathi et al [36], based on calcium
aggregation followed by differential centrifugation. The final
pellet containing the brush borders was resuspended and diluted
in 0.3% Triton X-100 for enzyme activity measurement and was
then stored at —80°C. The brush border preparation was charac-
terized by dosing specific enzyme markers [36].
The ACE activity was determined by a spectrophotometric
method (Sigma) based on the enzymatic reaction catalyzed by
ACE, where the furilacylphenylanylglycilglycine (FAPGG) was
hydrolized to furacylphenylalanine (FAP). The FAPGG hydroly-
sis produced a decrease in the absorbance at 340 nm, which was
directly proportional to the ACE activity of the sample. ACE
activity is expressed as relative units per milligram protein of
tissue and brush border membrane, as determined by the Lowry
method [37] and as units per ml in serum.
Statistical analysis
ANOVA and unpaired Student's t-test were used for protein-
uria, serum creatinine, serum total protein, serum cholesterol,
ACE activity and blood pressure measurements. The Kolmog-
orov-Smirnov test was used to assess the normal distribution of
the data. The Mann-Whitney U-test for nonparametric values was
used for semiquantitative variables. Differences were considered
significant if the P value was less than 0.05. Results are expressed
as mean SEM.
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Fig. 6. Localization of immune deposits by
immunofluorescence in nephritic rats. (A) In
untreated rats, IgG deposits were localized in
the glomerular mesangium and capillary walls.
(B) There was no change in the localization of
immune deposits in response to treatment.
Results
Evolution of disease
In this model of immune complex nephritis proteinuria appears
four to five weeks after intraperitoneal injection of ovalbumin,
and approximately three weeks later the animals develop ne-
phrotic syndrome and renal failure. At this time, glomerular
immune deposits are abundant both in mesangium and in all areas
of the capillary wall. There is also intense glomerular hypercellu-
larity with segmental fibrinoid necrosis and mononuclear cell
infiltration in the glomeruli and in the renal interstitium [25].
When proteinuria reached values between 20 to 50 mg/day
animals were randomly distributed into two groups: treated (33
10 mg/day) and untreated (30 14 mg/day; P = NS).
Evolution of proteinuria and renal function
The administration of quinapril (100 mg/liter in the drinking
water) avoided the development of intense proteinuria. At the
end of the study (21 days of treatment), the proteinuria in the
quinapril-treated rats was significantly reduced versus untreated
rats (79 28 vs. 589 73 mg/day; P < 0.001; Fig. 2). The
untreated nephritic animals developed renal failure compared to
healthy rats (creatinine clearance 236 52 vs. 307 21 jxl/min/
100 g; P < 0.01). In rats treated with quinapril, the renal function
improved with respect to nephritic rats (310 60 pi/min/100 g).
Biochemical parameters
Rats with nephritis presented hypoproteinemia and hypercho-
lesterolemia (Table 1). Rats treated with quinapril showed a
significant increase in total serum proteins and a significant
decrease in serum cholesterol levels compared to untreated rats
(Table 1).
Blood pressure
Mean systolic blood pressure in all rats was in the normotensive
range throughout the three weeks of study. No change in systolic
blood pressure in nephritic rats (119 7 mm Hg) versus controls
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Fig. 7. Mononuclear cell infiltration in the glomeruli and interstitium. The
quantitation of the infiltrating glomerular (A) and interstitial (B) cells was
performed by immunoperoxidase technique. Bars represent untreated
nephritis (U), quinapril-treated nephritis (LI), healthy-control () and
quinapril-treated control rats (). The values are expressed as mean
SEM. N = 5 to 6 per group. < 0.05; < 0.005 quinapril versus
untreated rats.
(118 7 mm Hg) was noted. Treatment with quinapril did not
modify the systolic pressure either in rats with nephritis (117 11
mm Hg) or in healthy controls (115 8 mm Hg; P NS; Fig. 3).
Morphological studies
Previous studies from our group have detailed the morpholog-
ical aspects of glomerular lesions [25]. In brief, in untreated rats
there was glomerular hypercellularity, mesangial matrix expan-
sion, segmental fibrinoid necrosis, glomeruloscierosis, and mono-
nuclear cell infiltration in the glomeruli and in the interstitium
(Figs. 4 and 5). After three weeks of treatment with quinapril, we
noted a significant decrease in the glomerular cellularity, matrix
expansion, glomerular sclerosis, interstitial infiltrates and tubular
atrophy (Figs. 4 and 5). A positive linear correlation was found
between the glomerular sclerosis, tubular atrophy and proteinuria
(P < 0.005).
This nephritis is characterized by the presence of immune
deposits in all glomerular areas [25]. Immune complexes can
stimulate mesangial cells proliferation and extracellular matrix
synthesis, through the activation of cytokine and growth factor
synthesis [38, 39]. Quinapril treatment reduced slightly, but not
significantly, the glomerular immune deposit score. Nevertheless,
deposits were still observed in the mesangium and glomerular
capillary wall in both groups of animals (2.0 0.6 quinapril-
treated vs. 2.3 0.4 untreated rats; light microscopy, semiquan-
titative score, P NS). Furthermore, immunofluorescence stud-
ies showed that there was no change in the localization and
intensity of IgG deposits (Fig. 6). Although previous studies have
demonstrated that Ang II modifies mesangial trafficking of mac-
romolecules [40], the absence of a significant reduction in the
amount of immune deposits in treated animals suggests that the
beneficial effect of quinapril is not due to this mechanism.
We also studied the phenotype of glomerular and interstitial
inflammatory cellular infiltrates by monoclonal antibodies and
indirect immunoperoxidase technique. Rats treated with quinapril
for three weeks had less glomerular total leukocytes (OX1, 2.7
0.9 vs. 7.5 0.4, cells/glomerulus, P < 0.05), T lymphocytes
(W3/13, 3.2 0.7 vs. 5.0 1.1, P < 0.05) and monocytes/
macrophages (ED1, 5.1 1.9 vs. 7.6 0.1, P < 0.05) than
untreated rats with nephritis (Figs. 7A and 8). The effect of
quinapril on the interstitial cellular infiltrates was more marked,
with important reduction in the number of leukocytes (91 14 vs.
343 180 cells/mm2 untreated rats, P < 0.005), T lymphocytes
(60 9 vs. 262 45, P < 0.005) and macrophages (37 8 vs. 149
14, P < 0.005) that approached normal values (Fig. 7B).
Extracellular matrix proteins
In normal kidney, fibronectin is present in the mesangium and
along the glomerular basement membrane. During glomerular
injury increased fibronectin and collagen IV deposition is fre-
quently observed [41, 421.
In animals with nephritis, the immunofluorescence studies
showed that fibronectin and collagen type IV increased in the
mesangium with extension to the capillary wall, and appeared in
the tubular basement membrane and in interstitium (Fig. 9). In
quinapril-treated rats, an important diminution in the glomerular
deposition of both proteins was noted (Fig. 9). By contrast, with
this semiquantitative technique, no clear differences were found in
interstitial collagens in response to treatment (data not shown).
In the renal cortex of untreated nephritic rats, dot blot studies
showed a 25-fold increase in fibronectin mRNA, and an eightfold
increase in collagen type IV mRNA, as compared to healthy rats
(Fig. 10). The mRNA of interstitial collagens type I and III was
also increased, although to a lesser extent (3.7-fold and 2.8-fold,
respectively; Fig. 10). The increase in matrix proteins mRNA in
the kidney, roughly correlated with the findings on immunofluo-
rescence, indicates that the accumulation of renal matrix proteins
was due to increased gene transcription, as occurs in other renal
diseases [43].
The treatment with quinapril down-regulated the expression of
fibronectin, and collagens IV, I and III (Fig. 10). Compared to
untreated nephritis, collagen type IV showed the greatest de-
crease (86%), followed by fibronectin (65%) and the interstitial
collagens I and III (both around 40%).
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Fig. 8. Effect of quinapril on glomerular
infiltration by macrophages. Representative
microphotographs of immunoperoxidase
staining sections. (A) Note intense glomerular
infiltration by macrophages (ED1 + cells) in
untreated rat. (B) Discrete presence of
macrophages in the glomerulus of a quinapril-
treated animal.
Renal TGF-pJ mRNA expression
In experimental nephritis, a close association between elevated
TGF-/31 mRNA expression and the development of glomerular
injury has been described [I• A Northern blot analysis of cortical
TGF-pl mRNA expression in control rats showed a weak 2.5 Kb
band (Fig. 11), suggesting that there was a low level of expression
of this growth factor in the cortex. In nephritic rats, there was a
marked increase in cortical TGF-f31 mRNA, which decreased in
quinapril-treated rats. By contrast, there was no increase in
medullary TGF-131 mRNA (data not shown). Dot blot analysis
showed similar results (Fig. 11).
ACE activity in serum and kidney
Serum ACE activity of rats with nephritis did not differ from
controls (Fig. 12A). ACE activity in the cortex of rats with
nephritis was significantly elevated compared to control rats (P <
0.005; Fig. 12B). These results suggest a different behavior
between circulating and tissue renal RAS in this model.
In a parallel group of animals with nephritis, we determined
ACE activity in the glomeruli and in the brush border membrane
of the renal cortex. Glomerular ACE activity did not differ from
controls. By contrast, brush border ACE activity, that was about
100 times higher than in the original cortical homogenates, was
elevated compared to controls (P < 0.05; Fig. 12C), suggesting
that the observed increase in cortex ACE activity was chiefly due
to the brush border membrane. ACE activity in medulla increased
in a more modest manner, not reaching statistical significance
(Fig. 12B). This suggests that ACE activity is regulated according
to location in renal tissue.
In response to quinapril, serum ACE was completely inhibited
(96%; Fig. 12A). ACE activity in the cortex and renal medulla was
inhibited by 68 and 79%, respectively, in response to quinapril
treatment (Fig. 12B).
Discussion
The beneficial effect of ACE inhibitors on the progression of
renal disease has been demonstrated in different animal models
associated or not to hypertension [6, 7, 16], but the precise
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Fig. 9. Immunofluorescence detection of exrracellular matth components.
In normal rats, flbronectin was deposited in mesangial areas. Note an
intense staining in the glomerulus of nephritic rats (A), which
diminished in quinapril-treated rats (B).
mechanism of their actions remains unknown. In this work, we
have studied the effect of ACE inhibition in a normotensive model
of glomerular immune injury, characterized by immune deposits
in all glomerular areas that morphologically resemble human
mesangiocapillary glomerulonephritis and active lupus nephritis
[25, 26].
In this model, untreated nephritic rats developed massive
nephrotic syndrome and renal failure approximately three weeks
after the onset of proteinuria [26], without modification of blood
pressure. The administration of quinapril, an ACE inhibitor with
strong tissue enzyme binding, to animals with established nephri-
tis resulted in significantly less proteinuria and preservation of
renal function.
Progressive renal scarring is associated with glomerular and
interstitium infiltration by inflammatory cells [1]. In untreated
nephritic rats, we observed infiltration of macrophages and T
cells. In animals treated with quinapril there was a significant
reduction in glomerular and interstitial infiltration. This effect
may be one of the mechanisms that ameliorates the evolution of
renal sclerosis. These results could be explained by the modifica-
tion of the proliferative and chemoattractant effects of Ang II
[17]. In this sense, in vivo infusion of Ang II induced a marked
vascular, glomerular and tubulointerstitial damage with increased
proliferation of renal resident cells and inflammatory cell recruit-
ment [45].
As it occurs in other progressive glomerulonephritis [1, 2], in
this model of immune nephritis, untreated rats presented an
accumulation of extracellular matrix in the glomeruli and the
interstititum. A marked increase in mRNA expression of normal
constituents of the glomerular extracellular matrix and of inter-
stitial collagens was noted. By immunofluorescence, an increase in
the glomerular and interstitial deposition of the two matrix
proteins studied (fibronectin and type IV collagen) was also
observed. In nephritic rats receiving quinapril there was a dimi-
nution in the mesangial expansion and glomerular sclerosis,
accompanied by a marked down-regulation in the renal cortex
gene expression of fibronectin and collagen IV. These results
suggest that the beneficial effect of ACE inhibition on extracellu-
lar matrix synthesis may occur at the transcriptional level. In
quinapril-treated rats the tubulointerstitial area was almost nor-
mal. The protection conferred by quinapril could be secondary to
the diminution of proteinuria or to the inhibition of the local
components of the RAS, as occurs in models of interstitial fibrosis
[14, 46]. These data are in agreement with those observed in the
unilateral ureteral ligation model, in the sense that treatment with
enalapril dramatically diminished the interstitial fibrosis and the
gene expression of matrix proteins [46].
TGF-3 is a multifunctional cytokine that plays a major biolog-
ical role in the regulation of extracellular matrix deposition [47,
48]. TGF-J3 gene expression is increased in several models of
acute and chronic renal injury in parallel with extracellular matrix
expansion [49]. Recent studies have stressed the interaction of
RAS and TGF-j3. Ang II induces TGF-f3 mRNA expression in
renal cells [19—21]. The in vivo subcutaneous infusion of Ang II
led to increased glomerular TGF-p gene expression [19]. These
data suggest that Ang II directly induces TGF-/3, which in turn
induces fibrotic changes. In our experimental model, the maximal
glomerular and tubulointerstitial damage coincided with an aug-
mentation in TGF-J31 mRNA expression in the renal cortex. It
must be highlighted that the treatment with quinapril normalized
TGF-/31 gene expression. These data indicate that the observed
therapeutic effect on synthesis of extracellular matrix components
may be due to reduced TGF-pl gene expression.
An important finding of our work was that the beneficial effect
of quinapril occurred in the absence of high blood pressure.
Contrasting with the normal values of serum ACE activity in rats
with nephritis, a marked elevation of ACE activity was noted in
the renal cortex of those animals, chiefly in the brush border
membranes of renal proximal tubules, suggesting a local activa-
tion of RAS. The components of RAS have been found modified
in different models of renal injury as diabetic nephropathy,
obstruction nephropathy and uninephrectomized rats with high
protein intake [50—52]. In response to the treatment, serum ACE
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Fig. 9. (continued) In nephritic rats, type IV
collagen is found along the glomerular
basement membrane, in the mesangial matrix as
well as in the basement membrane of Bowman
capsule and in the tubuli in almost equal
amounts (C). Note that there is an increase in
type IV collagen deposition in mesangial matrix
of the glomerulus, that decreases in quinapril-
treated rats (D).
activity was completely suppressed in quinapril-treated rats. The
importance of inhibiting ACE activity in tissue rather than in
serum has recently been emphasized [3, I. At renal level ACE
activity was reduced by quinapril therapy between 60 to 80%, to
the same extent as observed by other authors employing similar
doses of quinapril in the neointima after vascular injury [53}.
Since ACE inhibition, besides reducing Ang II formation, also
increases bradykinin concentrations, with the subsequent genera-
tion of nitric oxide and prostanglandins, the possibility exists that
other mechanisms, independently of Ang II actions, could con-
tribute to the beneficial effect of ACE inhibitors. Further studies
employing Ang II or bradykinin receptor antagonists may be
necessary to solve this point.
In summary, we have demonstrated that, in a normotensive
model of immune nephritis, the administration of an ACE
inhibitor attenuates the development of massive proteinuria,
amelioriates the morphological lesions, and decreases the gene
expression of TGF-j31 and matrix proteins. The inhibition of the
Ang II actions on resident cell proliferation and matrix protein
synthesis, via TGF-13, may be another mechanism of the beneficial
effect of these drugs in immune and nonimmune glomerular
injury, independently of the presence of high blood pressure.
These data, together with those traditionally known about the
glomerular hemodynamic improvement by ACE inhibitors, pro-
vide additional evidence for the employment of these drugs in
patients with progressive renal disease.
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Fig. 10. Gene expression of matrix proteins in renal cortex. (A) Dot blot analysis. Serial dilutions of RNA from each rat were hybridized with appropriate
cDNA probes for fibronectin and type I, III and IV coflagens. A representative animal of each group is shown. N = 4 to 6 per group. (B) Densitometric
analysis of dot blot. Values were obtained from the second dot containing 20 jig RNA corrected by the density of 28S and are expressed as N-fold
increase over control, mean so of 4 to 6 animals per group. *p < 0.05.
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Fig. 11. Gene expression of TGF-J31 mRNA in renal cortex. (A) Dot blot analysis. Serial dilutions of RNA from each rat were hybridized with TGF-131.
The Figure shows a representative animal of each group. N = 4 to 6 per group. (B) Densitometric analysis of dot blot. Values were obtained from the
second dot containing 20 g RNA corrected by the density of 28S and were expressed as N-fold increase over control. Data are mean SD of 4 to
6 animals per group. *p < 0.05. (C) Northern blot. Animals were pooled (4 animals per group), 30 g of RNA were loaded. Ethidium bromide staining
showed the equivalent loading of RNA and its absence of degradation. Lane 1 (healthy controls); Lane 2 (untreated nephritis); Lane 3 (quinapril-treated
controls); Lane 4 (quinapril-treated nephritis).
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